Nurix Therapeutics (NRIX) Operating Expenses (2019 - 2026)

Nurix Therapeutics (NRIX) has 8 years of Operating Expenses data on file, last reported at $103.2 million in Q2 2026.

• On a quarterly basis, Operating Expenses rose 11.77% year-over-year to $103.2 million in Q2 2026; TTM through May 2026 was $397.9 million, a 24.81% increase from a year earlier, with the FY2025 full-year figure at $369.6 million, up 38.15% from the prior year.
• Operating Expenses for Q2 2026 stood at $103.2 million, up from $98.7 million in the prior quarter.
• Over the last five years, Operating Expenses for NRIX reached as high as $103.2 million in Q2 2026 and fell as low as $52.4 million in Q1 2022.
• Historically, Operating Expenses has averaged $71.9 million across 5 years, with a median of $61.2 million in 2024.
• Across the five-year window, Operating Expenses soared 77.31% in 2022 and advanced 0.51% in 2023, its largest moves.
• Year by year, Operating Expenses stood at $55.5 million in 2022, then increased by 9.05% to $60.5 million in 2023, then grew by 28.84% to $77.9 million in 2024, then rose by 24.03% to $96.7 million in 2025, then advanced by 6.8% to $103.2 million in 2026.
• Per Business Quant data, the three most recent Operating Expenses figures were $103.2 million in Q2 2026, $98.7 million in Q1 2026, and $96.7 million in Q4 2025.